An estimated 5.9 million Medicare enrollees are shut out of the program's $50 monthly GLP-1 price precisely because they carry a diagnosis the drugs are approved to treat, a quantified figure that had not previously been attached to the pilot's exclusion rules.
The number comes from KFF Health News reporting on the Bridge program published this week. The GLP-1 Bridge applies only to beneficiaries using the drugs solely for weight loss. Anyone with a condition the FDA has approved a GLP-1 to treat, including Type 2 diabetes and moderate to severe obstructive sleep apnea, is routed back to their standard Part D plan, where copays can run into the hundreds of dollars a month.
For households, the practical consequence is a coverage inversion that is easy to miss until a pharmacy rejection arrives. A beneficiary with obesity alone can pay $50. A beneficiary with obesity plus sleep apnea, who is sicker, can pay far more.
The Design Logic That Produces the Inversion
The exclusion is deliberate rather than an oversight, and understanding why clarifies the appeal pathway.
Federal law has long barred Medicare from covering drugs prescribed solely for weight loss. The Bridge exists as a time-limited demonstration outside that framework, which is what lets it cover obesity treatment at all. People with diabetes, sleep apnea, or metabolic liver disease already have a route to GLP-1 coverage inside Part D, so the pilot does not duplicate it. A KFF analysis found that of the 9.7 million Part D enrollees who met the Bridge clinical criteria, fewer than 4 million were eligible after exclusions were applied.
Juliette Cubanski, who directs the Program on Medicare Policy at KFF, said the Bridge was "designed to target those people who can't get GLP-1 coverage through Part D" but would still benefit from the drugs for weight loss.
CMS has described the 18-month pilot as a test of whether treating obesity earlier saves the program money before more costly chronic conditions develop. That framing explains the boundary. The pilot is a prevention experiment, and people who already have the downstream conditions fall outside the scope of the question being tested.
The gap is that having a theoretical Part D route is not the same as having an affordable one. One beneficiary profiled in the reporting, a retired professor in New Jersey with a BMI of 42 and a history of quadruple bypass surgery, was denied Bridge pricing because of his sleep apnea diagnosis and left his prescription unfilled, as Fortune reported in republishing the account.
Steps Available to Beneficiaries Who Were Denied Bridge Pricing
A Bridge denial for a qualifying diagnosis is not the end of the process, and it should not be confused with the billing rejections that dominated the program's first weeks.
MedicalDaily previously reported on pharmacy counter denials that turned away eligible seniors because claims were routed to their Part D plan instead of the Bridge processor. That was a technical problem with a technical fix. A denial based on a qualifying diagnosis falls into a different category, and the remedy lies within Part D rather than within the Bridge.
The first step is confirming which denial occurred. If the rejection cites eligibility rather than claim routing, the prescriber should pursue coverage through the beneficiary's Part D plan under the qualifying indication, which usually requires a prior authorization documenting diabetes, sleep apnea, or a cardiovascular indication.
The Appeal Ladder Most Beneficiaries Never Reach
From there, the standard Part D appeal ladder applies. A beneficiary can request a coverage determination, then a redetermination, and can ask the prescriber to file an exception request if the specific formulation is not on the formulary. Formulation matters more than patients expect. Under the Bridge, tirzepatide is covered only as the Zepbound KwikPen, not as vials or single-dose pens, and Part D formularies vary in which semaglutide and tirzepatide presentations they list.
Manufacturer patient assistance programs remain a separate channel, and eligibility should be confirmed directly with Novo Nordisk or Eli Lilly rather than assumed. Beneficiaries who cannot resolve a rejection can call 1-800-MEDICARE, and State Health Insurance Assistance Programs provide free counseling on appeals.
No one should stop or alter a prescribed medication because of a coverage letter. GLP-1 dosing is titrated, and an abrupt interruption should be managed by a clinician rather than by a pharmacy denial.
The Coverage Cliff Sitting Behind This Year's Rules
The exclusion question is nested within a larger timing problem that remains unresolved.
The Bridge runs through December 31, 2027. Its intended successor for Medicare, the BALANCE model, will not launch as planned in January 2027 because plan participation fell short of the threshold CMS had set at 80 percent of Part D enrollment. CMS extended the Bridge instead. The Medicaid component of BALANCE is still moving forward, and the agency has said the delay allows it to gather utilization data that plans said they lacked.
That matters for the excluded group in a specific way. If a permanent structure eventually folds obesity coverage into Part D, the distinction between weight-loss-only use and qualifying-diagnosis use may no longer determine price. Until then, the diagnosis on a chart continues to set the copay.
What remains unknown is substantial. CMS has not published how many Bridge applications have been denied on eligibility grounds, how many of the estimated 5.9 million excluded beneficiaries actually sought the discount, or how many later obtained GLP-1 coverage through Part D and at what cost. The pilot's savings hypothesis will not be testable for months.
The confirmed fact is that a qualifying diagnosis moves a Medicare beneficiary out of the $50 price and back into standard Part D cost sharing. The people most affected are older adults with obesity plus diabetes, sleep apnea, or metabolic liver disease, and the reasonable next step for them is a Part D prior authorization rather than a second Bridge application.
Key Questions Answered
Who is excluded from the $50 price? Beneficiaries with a condition the FDA has approved a GLP-1 to treat, including Type 2 diabetes, moderate to severe obstructive sleep apnea, and metabolic liver disease. An estimated 5.9 million enrollees fall into this group.
Why would a sicker patient pay more? The Bridge covers weight-loss-only use because Part D is barred from covering weight-loss drugs. People with a qualifying condition already have a Part D route, so the pilot sends them back to it, where copays are higher.
Is this the same as the pharmacy billing rejections? No. Those were routing errors that could be fixed by resubmitting to the Bridge processor. An eligibility denial requires pursuing Part D coverage instead.
What should someone do after an eligibility denial? Ask the prescriber to file a Part D prior authorization under the qualifying indication, then use the coverage determination and redetermination appeal steps if it is denied.
Does formulation affect coverage? Yes. Under the Bridge, tirzepatide is covered only as the Zepbound KwikPen, and Part D formularies differ on which semaglutide and tirzepatide presentations they include.
Should anyone stop their medication over a denial? No. GLP-1 dosing is titrated, and any change should be managed by a clinician, not triggered by a coverage letter.
When does the Bridge end? December 31, 2027. Its Medicare successor will not launch in 2027 after plan participation fell short, and no permanent replacement framework is in place.
